carboxylesterase 1

By Targets:	Carboxylesterase (CES) (9) Antibiotic (2) Apoptosis (9) Autophagy (2) Bacterial (2) Bcl-2 Family (2) c-Fms (1) Calcium Channel (1) DNA/RNA Synthesis (2) Ferroptosis (1) Fluorescent Dye (1) Free Fatty Acid Receptor (1) GLP Receptor (2) HDAC (3) Insulin Receptor (2) Isotope-Labeled Compounds (2) Mitochondrial Metabolism (1) NOD-like Receptor (NLR) (2) p38 MAPK (2) Reactive Oxygen Species (ROS) (2) Reference Standards (3) α-synuclein (2)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Endocrinology (2) Infection (2) Inflammation/Immunology (3) Metabolic Disease (7) Neurological Disease (4)

Targets Recommended: Carboxylesterase (CES)

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-134124

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .

HY-N0921

Dihydromethysticin (+)-Dihydromethysticin	Carboxylesterase (CES) NOD-like Receptor (NLR) Apoptosis	Cancer
Dihydromethysticin is an orally active natural active ingredient. Dihydromethysticin can be extracted from Piper methysticum. Dihydromethysticin inhibits carboxylesterase 1 (K_i = 68.2 μM) and CYP2A5. Dihydromethysticin upregulates NLRC3 and induces Apoptosis. Dihydromethysticin exhibits anticancer activity against colorectal cancer and lung adenoma .

HY-19772

GSK3117391 ESM-HDAC391; CHR-5154; HDAC-IN-3	HDAC c-Fms	Inflammation/Immunology
GSK3117391 (ESM-HDAC391; CHR-5154; HDAC-IN-3) is an orally active HDAC inhibitor with a IC₅₀ of 55 nM. Using esterase-sensitive motif technology, GSK3117391 is selectively converted into its active acid metabolite HDAC189 in cells expressing carboxylesterase-1. GSK3117391 induces sustained global protein acetylation in monocytes, inhibits the production of proinflammatory cytokines, depletes circulating monocytes, downregulates the expression of CSF1R, and inhibits monocyte adhesion and differentiation. GSK3117391 can be used in the research of chronic inflammatory diseases .

HY-N1377

Nevadensin Lysionotin	Carboxylesterase (CES) DNA/RNA Synthesis Apoptosis Bacterial	Infection Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Nevadensin (Lysionotin), a natural flavonoid, is a selective *human carboxylesterase 1* (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage** in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-110390

GR148672X	Carboxylesterase (CES) Free Fatty Acid Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Ferroptosis Apoptosis	Cardiovascular Disease Cancer
GR148672X is an inhibitor of carboxylesterase 1 (CES1) and hepatic microsomal triglyceride hydrolase (TGH). GR148672X blocks the catalytic activity of CES1, impairs the functions of triglyceride and cholesteryl ester lipase, reduces triglyceride mobilization and secretion, and decreases apolipoprotein B-100 secretion in primary rat hepatocytes. Under low-glucose conditions, GR148672X inhibits the survival of colorectal cancer cells by reducing free fatty acid availability, inducing toxic triglyceride accumulation, ROS production, mitochondrial damage, ferroptosis and apoptosis. GR148672X can be used in studies related to colorectal cancer and atherosclerosis .

HY-144809

*Pancreatic lipase/Carboxylesterase 1-IN-1*	Carboxylesterase (CES)	Metabolic Disease
Pancreatic lipase/Carboxylesterase 1-IN-1 (Compound 39) is a potent dual inhibitor of pancreatic lipase (PL) and *human carboxylesterase 1A (hCES1A)* with IC₅₀ values of 2.13 µM and 0.055 µM against PL and hCES1A .

HY-106409

Tefinostat 1 Publications Verification CHR-2845	HDAC Apoptosis	Cancer
Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase (HDAC) inhibitor. Tefinostat can be cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Tefinostat can be used for the research of leukaemias .

HY-W143997

Dibutyl malate DL-Malic acid dibutyl ester	Carboxylesterase (CES)	Others
Dibutyl malate is a substrate of *carboxylesterase* .

HY-147331

Oseltamivir acid methyl ester	Antibiotic Carboxylesterase (CES)	Neurological Disease
Oseltamivir acid methyl ester is a precursor form of the neuraminidase inhibitor and antiviral oseltamivir acid. Oseltamivir acid methyl ester is converted to oseltamivir acid by carboxylesterase 1 (CES1) .

HY-W354821

4-Methylumbelliferyl Decanoate 4-MUD	Fluorescent Dye	Metabolic Disease
4-Methyl-2-oxo-2H-1-benzopyran-7-yl decanoate is a fluorogenic substrate used to follow the hydrolytic activity of carboxylesterases .

HY-P2424

Cholecystokinin-J CCK-J	Calcium Channel	Others
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca ²⁺ release .

HY-147331A

Oseltamivir acid methyl ester hydrochloride	Antibiotic Carboxylesterase (CES)	Neurological Disease
Oseltamivir acid methyl ester hydrochloride is a precursor form of the neuraminidase inhibitor and antiviral oseltamivir acid. Oseltamivir acid methyl ester hydrochloride is converted to oseltamivir acid by carboxylesterase 1 (CES1) .

HY-106409R

Tefinostat (Standard) CHR-2845 (Standard)	Reference Standards HDAC Apoptosis	Cancer
Tefinostat (Standard) is the analytical standard of Tefinostat (HY-106409). This product is intended for research and analytical applications. Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase (HDAC) inhibitor. Tefinostat can be cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Tefinostat can be used for the research of leukaemias .

HY-N0921R

Dihydromethysticin (Standard) (+)-Dihydromethysticin (Standard)	Reference Standards Carboxylesterase (CES) NOD-like Receptor (NLR) Apoptosis	Cancer
Dihydromethysticin (Standard) is the analytical standard of Dihydromethysticin (HY-N0921). This product is intended for research and analytical applications. Dihydromethysticin is an orally active natural active ingredient. Dihydromethysticin can be extracted from Piper methysticum. Dihydromethysticin inhibits carboxylesterase 1 (K_i = 68.2 μM) and CYP2A5. Dihydromethysticin upregulates NLRC3 and induces Apoptosis. Dihydromethysticin exhibits anticancer activity against colorectal cancer and lung adenoma .

HY-N1377R

Nevadensin (Standard) Lysionotin (Standard)	Carboxylesterase (CES) Reference Standards DNA/RNA Synthesis Apoptosis Bacterial	Infection Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Nevadensin (Standard) (Lysionotin (Standard)) is the analytical standard of Nevadensin (HY-N1377). This product is intended for research and analytical applications. Nevadensin, a natural flavonoid, is a selective *human carboxylesterase 1* (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage** in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities.

Cat. No.	Nombre del producto	Type

HY-W354821

4-Methylumbelliferyl Decanoate 4-MUD	Fluorescent Dyes
4-Methyl-2-oxo-2H-1-benzopyran-7-yl decanoate is a fluorogenic substrate used to follow the hydrolytic activity of carboxylesterases .

Cat. No.	Nombre del producto	Target	Research Area

HY-134124

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P2424

Cholecystokinin-J CCK-J	Calcium Channel	Others
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca ²⁺ release .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-N0921

Dihydromethysticin (+)-Dihydromethysticin	Productos naturales other families Classification of Application Fields Plants Inflammation/Immunology Disease Research Fields Source Classification	Carboxylesterase (CES) NOD-like Receptor (NLR) Apoptosis
Dihydromethysticin is an orally active natural active ingredient. Dihydromethysticin can be extracted from Piper methysticum. Dihydromethysticin inhibits carboxylesterase 1 (K_i = 68.2 μM) and CYP2A5. Dihydromethysticin upregulates NLRC3 and induces Apoptosis. Dihydromethysticin exhibits anticancer activity against colorectal cancer and lung adenoma .

HY-N1377

Nevadensin Lysionotin	Flavonoids other families Classification of Application Fields Flavones Phenols Polyphenols Metabolic Disease Plants Inflammation/Immunology Disease Research Fields Source Classification	Carboxylesterase (CES) DNA/RNA Synthesis Apoptosis Bacterial
Nevadensin (Lysionotin), a natural flavonoid, is a selective *human carboxylesterase 1* (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage** in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities .

HY-N0921R

Dihydromethysticin (Standard) (+)-Dihydromethysticin (Standard)	Structural Classification Productos naturales Microorganisms other families Plants Source Classification	Reference Standards Carboxylesterase (CES) NOD-like Receptor (NLR) Apoptosis
Dihydromethysticin (Standard) is the analytical standard of Dihydromethysticin (HY-N0921). This product is intended for research and analytical applications. Dihydromethysticin is an orally active natural active ingredient. Dihydromethysticin can be extracted from Piper methysticum. Dihydromethysticin inhibits carboxylesterase 1 (K_i = 68.2 μM) and CYP2A5. Dihydromethysticin upregulates NLRC3 and induces Apoptosis. Dihydromethysticin exhibits anticancer activity against colorectal cancer and lung adenoma .

HY-N1377R

Nevadensin (Standard) Lysionotin (Standard)	Structural Classification Flavonoids other families Flavones Phenols Polyphenols Plants Source Classification	Carboxylesterase (CES) Reference Standards DNA/RNA Synthesis Apoptosis Bacterial
Nevadensin (Standard) (Lysionotin (Standard)) is the analytical standard of Nevadensin (HY-N1377). This product is intended for research and analytical applications. Nevadensin, a natural flavonoid, is a selective *human carboxylesterase 1* (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage** in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities.

Species:	Human (2) Mouse (1)
Tag:	His (3)
Source:	HEK293 (2) P. pastoris (1)

Cat. No.	Compare	Nombre del producto	Species	Source	Image

HY-P7730

	Carboxylesterase 1 Protein, Human (HEK293, His) rHucarboxylesterase 1, His; CES1; carboxylesterase 1; Cocaine carboxylesterase; Serine Esterase 1; Triacylglycerol Hydrolase	Human	HEK293
	Carboxylesterase 1 Protein, Human (HEK293, His) is an approximately 60.0 kDa human carboxylesterase 1 protein with a His-flag. Human Carboxylesterase 1 is the key liver microsomal enzyme that takes part in detoxification and metabolism.

HY-P703886

	Carboxylesterase 1 Protein, Human (549a.a, HEK293, His) carrHucarboxylesterase 1, His; CES1; carboxylesterase 1; Cocaine carboxylesterase; Serine Esterase 1; Triacylglycerol Hydrolase	Human	HEK293
	Carboxylesterase 1 Protein, Human (549a.a, HEK293, His) is the recombinant human-derived Carboxylesterase 1 protein, expressed by HEK293, with C-His tag.

HY-P71802

	Carboxylesterase 1C Protein, Mouse (P.pastoris, His) carboxylesterase 1C; Ces N; Ces1c; Ee 1; Ee 4; Ee1; Es N; Es1; Es4; EsN; EST1C_MOUSE; Esterase 1; Liver carboxylesterase N; Lung surfactant convertase; PES-N; PESN	Mouse	P. pastoris
	The carboxylesterase 1C protein is essential for xenobiotic detoxification and ester/amide prodrug activation, as well as participating in extracellular metabolism. Its multifunctional effects include processing of pulmonary surfactant. Carboxylesterase 1C Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived Carboxylesterase 1C protein, expressed by P. pastoris , with N-6*His labeled tag.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

Cat. No.	Nombre del producto	Chemical Structure

HY-114118S1

Semaglutide-d8 tetraTFA
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Compare	Nombre del producto	Application	Reactivity	Image

HY-P82583

	*Liver Carboxylesterase 1* Antibody (YA2328)** ACAT; CE 1; CEH; CES1; CES2; CESDD1; Egasyn; ES-HTEL; ES-x; Es22; Esterase 22; hCE 1; HMSE; HMSE1; REH; SES1; TGH; Triacylglycerol hydrolase	WB, IP, FC	Human, Mouse, Rat
	Liver Carboxylesterase 1 Antibody (YA2328) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Liver Carboxylesterase 1.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

carboxylesterase 1

Inhibitors & Agonists

Fluorescent Dyes

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products